Dare Bioscience Files 8-K on Financials

Ticker: DARE · Form: 8-K · Filed: Aug 12, 2024 · CIK: 1401914

Sentiment: neutral

Topics: financial-condition, results-of-operations, filing

TL;DR

Dare Bioscience dropped an 8-K on financials, check it for the latest numbers.

AI Summary

On August 12, 2024, Dare Bioscience, Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, along with financial statements and exhibits. No specific financial figures or significant events were detailed in the provided excerpt.

Why It Matters

This filing indicates Dare Bioscience is providing updates on its financial status and operational results, which is crucial for investors to assess the company's performance and outlook.

Risk Assessment

Risk Level: low — The provided text is a standard 8-K filing notification and does not contain specific financial results or material events that would indicate a high risk.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing by Dare Bioscience, Inc.?

The primary purpose of this 8-K filing is to report on the company's Results of Operations and Financial Condition, along with Financial Statements and Exhibits.

On what date was this 8-K report filed or effective?

The report was filed as of August 12, 2024, and the date of the earliest event reported is also August 12, 2024.

Where are Dare Bioscience, Inc.'s principal executive offices located?

Dare Bioscience, Inc.'s principal executive offices are located at 3655 Nobel Drive, Suite 260, San Diego, CA 92122.

What is the Commission File Number for Dare Bioscience, Inc.?

The Commission File Number for Dare Bioscience, Inc. is 001-36395.

What is the Standard Industrial Classification (SIC) code for Dare Bioscience, Inc.?

The Standard Industrial Classification (SIC) code for Dare Bioscience, Inc. is 2834, which corresponds to Pharmaceutical Preparations.

Filing Stats: 524 words · 2 min read · ~2 pages · Grade level 10.5 · Accepted 2024-08-12 16:01:31

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. DAR BIOSCIENCE, INC. Dated: August 12, 2024 By: /s/ Sabrina Martucci Johnson Name: Sabrina Martucci Johnson Title: President and Chief Executive Officer -3-

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing